MANTLE CELL LYMPHOMA (MCL)
Clinical trials for MANTLE CELL LYMPHOMA (MCL) explained in plain language.
Never miss a new study
Get alerted when new MANTLE CELL LYMPHOMA (MCL) trials appear
Sign up with your email to follow new studies for MANTLE CELL LYMPHOMA (MCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New CAR t therapy aims to stop High-Risk lymphoma early
Disease control Not yet recruitingThis study tests a new cell therapy (MB-CART2019.1) as an early, intensive treatment for people with high-risk mantle cell lymphoma. About 52 participants will receive the therapy after initial chemotherapy to see if it can keep the cancer from coming back. The main goal is to me…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE2 • Sponsor: Miltenyi Biomedicine GmbH • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Colombia launches first CAR-T trial for Hard-to-Treat blood cancers
Disease control Not yet recruitingThis study aims to bring CAR-T cell therapy to Colombia for people with certain blood cancers that have come back or not responded to treatment. It has two parts: first, setting up the necessary partnerships and facilities to produce the therapy locally, and second, a small trial…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: NA • Sponsor: GUSTAVO SALGUERO • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for hard-to-treat lymphoma: drug cocktail targets cancer after other treatments fail
Disease control Not yet recruitingThis study tests a combination of four drugs (zuberitamab, selinexor, dexamethasone, and thalidomide) in 30 adults with mantle cell lymphoma that came back or didn't respond to BTK inhibitors. The goal is to shrink tumors and keep them from returning. Participants first get 6 cyc…
Matched conditions: MANTLE CELL LYMPHOMA (MCL)
Phase: PHASE4 • Sponsor: Zhengzhou University • Aim: Disease control
Last updated May 11, 2026 20:49 UTC